Thirteen antibodies approved (FDA) for oncologic uses (2011)

Name	Type	Trade name(s)	Target(s)	Cancer type
Alemtuzumab (2001)	Humanized	Campath	CD52	● B-cell chronic lymphocytic leukemia (B-CLL)
Bevacizumab (2004)	Humanized	Avastin	Vascular endothelial growth factor (VEGF)	● Metastatic renal cell carcinoma, in combination with interferon-α ; ● Glioblastoma with progressive disease following prior therapy; ● Unresectable, locally advanced, recurrent, or metastatic, non-squamous, non-small cell lung cancer. Initial systemic treatment, in combination with carboplatin and paclitaxel; ● Metastatic carcinoma of the colon or rectum. Second-line treatment in combination with intravenous 5-fluorouracil-based chemotherapy; ● Metastatic colorectal cancer. First-line treatment
Brentuximab vedotin (2011)	Chimeric	Adcentris	CD30	● Hodgkin lymphoma (HL); ● Anaplastic large cell lymphoma (ALCL)
Cetuximab (2004)	Chimeric	Erbitux	Epidermal growth factor receptor (EGFR)	● EGFR-expressing metastatic colorectal carcinoma. Cetuximab is used alone in patients intolerant to irinotecan-based chemotherapy or in combination with irinotecan in patients refractory to irinotecan-based therapy; ● Locally or regionally advanced squamous-cell carcinoma of head and neck. In combination with radiation therapy; ● Recurrent or metastatic squamous-cell carcinoma of head and neck. Cetuximab is used alone in patients for whom platinum-based therapy has failed
Denosumab (2010)	Human	Prolia Xgeva	RANK Ligand (RANKL) inhibitor	● Prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors
Gemtuzumab (2000)	Humanized	Mylotarg	CD33	● Acute myeloid leukemia that had relapsed. Gemtuzumab was used in patients 60 years or older who were not able to receive other chemotherapy.
Ibritumomab tiuxetan (2002)	Murine	Zevalin	CD20	● Certain types of B-cell non-Hodgkin lymphoma (NHL). Ibritumomab tiuxetan is used in patients who have been treated with chemotherapy or with rituximab alone and have not gotten better or have had a relapse. Ibritumomab tiuxetan is combined with a radioactive substance and given with rituximab, as a type of radioimmunotherapy.
Ipilimumab (2011)	Human	Yervoy	CTLA-4	● Unresectable or metastatic melanoma
Ofatumumab (2009)	Human	Arzerra	CD20	● Chronic lymphocytic leukemia no longer being controlled by other forms of chemotherapy (fludarabine, alemtuzumab)
Panitumumab (2006)	Human	Vectibix	Epidermal growth factor receptor (EGFR)	●  EGFR-expressing, metastatic colorectal carcinoma with disease progression or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens
Rituximab (1997)	Chimeric	Rituxan Mabthera	CD20	● Previously untreated follicular CD-20 positive B-cell. In combination with chemotherapy; ● Chronic lymphocytic leukemia (CLL). In combination with fludarabine and cyclophosphamide; ● Low grade or follicular B-cell, CD20-positive non-Hodgkin’s lymphoma. In combination or following cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy; ● Diffuse large B-cell, CD20-positive, non-Hodgkin’s lymphoma. First-line treatment in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or other anthracycline-based chemotherapy regimens
Tositumumab and  Iodine I 131 Tositumomab (2003)	Murine	Bexxar	CD20	● CD-20 positive, follicular non-Hodgkin lymphoma, with or without transformation that is refractory to rituximab and has relapsed following chemotherapy
Trastuzumab (1998)	Humanized	Herceptin	ErbB2	● HER2 (ErbB2)-overexpressing metastatic breast tumors

Note: the bispecific antibody catumaxomab (trade name Removab) was approved in 2009 in the European Union. It is approved for the treatment of malignant ascites in patients with Epithelial Cell Adhesion Molecule (EpCAM)-positive cancer if a standard therapy is not available